Results tagged “ragweed” from Allergy

The prescription antihistamine Astelin(R) (azelastine HCl) Nasal Spray(R) relieved the major symptoms of pollen allergy, including sneezing, runny nose and congestion, within 15 minutes of application compared to placebo and maintained efficacy at all time points for 8 hours in a randomized, single dose, double-blind, placebo- controlled study, MedPointe Pharmaceuticals announced today.

In addition, a group of patients treated with intranasal Nasonex(R) (mometasone furoate monohydrate) did not show symptom improvement compared to placebo during the eight hour study period. Data from the 450-patient study, conducted in a controlled environmental exposure unit (EEU), were presented at the 2007 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Diego, California.

BERKELEY, Calif., Jan. 8 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX ) announced today that the analysis of interim one-year data from its two-year DARTT ragweed allergy trial indicated that no meaningful ragweed-specific allergic disease was observed in the study population, making it impossible to measure the therapeutic effect of TOLAMBA treatment. In all three arms of the study, including the placebo arm, minimal change from baseline was observed in the main efficacy measure of the study, the total nasal symptom score (TNSS). The company indicated that in the placebo and treated groups, the change from baseline TNSS was very low; not clinically significant; and substantially lower than what has been observed in prior trials.

"In effect, we saw three patient groups with no measurable disease during the ragweed season. This result was unexpected, though these challenges are well known to occur in allergy drug development. Due to the fact that no clinically significant disease was seen in the study population, it was impossible to measure the effect of our intervention," noted Dino Dina, MD, president and chief executive officer. Dina continued, "We are working closely with our consultants and investigators to review the data in detail and determine the future of the program."

COPENHAGEN (Reuters) - U.S. drug maker Schering-Plough Corp. <SGP.N> will develop and sell Denmark's ALK-Abello anti-allergy drug Grazax in North America, the Danish company said on Wednesday.

Shares in the Danish company rose 7.1 percent to 1,550 crowns on the news.

The drug treats grass pollen, house dust mite and ragweed allergies. The two companies will develop and sell it in the United States, Canada and Mexico, with Schering-Plough acquiring exclusive license rights.

Ragweed allergies makes millions of us miserable with symptoms from red, watery eyes to excessive sneezing. But now a new treatment could soon leave you allergy-free.

It's ragweed season again and oncology nurse Kim Brandt is just one of 36 million Americans allergic to the wild plant.

Kim Brandt, RN, ragweed allergy sufferer: "I would be sneezing, running, watery eyes, itchy nose and nasal congestion."

Sick of the symptoms, Kim joined a study on a new approach called rush immunotherapy.

Finally some good news on Allergy treatment. Sublingual Immunotherapy instead of shots. No more skin penetrating and direct injections into the blood. The allergen will go via "normal" way, i.e. the immune system will get proper warning and will act accordingly

"I have to remember to take it every morning," Mrs. Pilarski said. "Other than that, it's very convenient."

Ok, I understand that there's a price to pay for the safe medicine - a need to remember to take it. However, I think it's not that hard.

Anyways, I think this is a great start.

Read more below

NBC -- Changing leaves and cooler temperatures aren't the only signs that Autumn is here! For many people, itchy eyes and runny noses mark the beginning of Fall.

But if you depend on a drug store remedy to ease your allergy suffering, you may want to take a second look at the label.

For millions, the start of fall means much more than the end of mowing season!

Americans accustomed to the seasonal misery of sneezing, runny noses and itchy, watery eyes caused by ragweed pollen might one day benefit from an experimental allergy treatment that not only requires fewer injections than standard immunotherapy, but leads to a marked reduction in symptoms that persists for at least a year after therapy has stopped, according to a new study in the October 5 issue of i The New England Journal of Medicine (NEJM). The research was sponsored by the Immune Tolerance Network, which is funded by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), both components of the National Institutes of Health (NIH), and the Juvenile Diabetes Research Foundation International.

BALTIMORE, Oct. 5 (UPI) -- Baltimore researchers have successfully used an experimental DNA-based vaccine to protect against ragweed allergies, commonly known as hay fever.

Patients receiving the vaccine showed an average 60 percent reduction in allergy symptoms compared to those receiving a placebo, say researchers at The Johns Hopkins University School of Medicine.

The NEW ENGLAND JOURNAL OF MEDICINE (Vol. 355, October 5, 2006, No.14), today reported that a new approach to allergy therapy not only reduced the acute allergic responses of individuals with ragweed allergies but also sustained that effect for over 12 months. The novel treatment, called "AIC" in the paper, is a TLR9 agonist linked to ragweed allergen, developed by Dynavax Technologies Corporation (Nasdaq: DVAX).